Psyence Biomedical (NASDAQ:PBM) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Psyence Biomedical (NASDAQ:PBM) to a hold rating in a research note released on Saturday morning.

Psyence Biomedical Stock Performance

Shares of NASDAQ PBM opened at $4.36 on Friday. Psyence Biomedical has a 1-year low of $2.92 and a 1-year high of $699.19. The business has a fifty day moving average price of $4.32 and a 200 day moving average price of $9.20.

Institutional Investors Weigh In On Psyence Biomedical

Hedge funds and other institutional investors have recently bought and sold shares of the company. Virtu Financial LLC acquired a new position in shares of Psyence Biomedical during the fourth quarter worth $27,000. Essential Planning LLC. acquired a new stake in shares of Psyence Biomedical in the 4th quarter worth $163,000. Finally, Harraden Circle Investments LLC purchased a new position in Psyence Biomedical during the 4th quarter worth $385,000. Hedge funds and other institutional investors own 77.44% of the company’s stock.

Psyence Biomedical Company Profile

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company’s lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care.